×
About 24,893 results

Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)
https://clinicaltrials.gov/ct2/show/NCT03473340

Jan 21st, 2022 - Greater than 50% of lung transplant recipients show signs of chronic lung allograft dysfunction (CLAD) by 5 years post-transplantation.Therapies to prevent or slow CLAD are lacking. Anti-fibrotic therapies may offer an avenue to prevent progression of CLAD and prolong allograft survival. This study investigates if Pirfenidone therapy will stabilize lung function decline and slow progression of ...

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
https://clinicaltrials.gov/ct2/show/NCT04467723

Jan 21st, 2022 - The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans
https://clinicaltrials.gov/ct2/show/NCT02781519

Jan 21st, 2022 - The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.

A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS)
https://clinicaltrials.gov/ct2/show/NCT04586010

Jan 21st, 2022 - A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.

Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS)
https://clinicaltrials.gov/ct2/show/NCT04586023

Jan 21st, 2022 - A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
https://clinicaltrials.gov/ct2/show/NCT04704271

Jan 21st, 2022 - To characterize the acute effects of vaporized THC in women relative to men and to begin probing the mechanisms that may underlie gender differences.

Preemptive Use of the Nicotine Patch for Postoperative Pain Relief After Open Abdominal Surgery
https://clinicaltrials.gov/ct2/show/NCT00790829

Jan 21st, 2022 - Study patients include nonsmokers aged 18-75 undergoing open abdominal wall surgery under general anesthesia. If the patient smokes, receives a regional anesthetic such as an epidural, or is pregnant, then he/she is excluded from the study. There are two randomized study groups. Group B receives a seven-milligram transdermal patch and Group A receives a placebo patch. Generic seven-milligram ni...

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I
https://clinicaltrials.gov/ct2/show/NCT02811510

Jan 21st, 2022 - To characterize the acute effects of oral Dronabinol (10 mg capsule) in women relative to men and to begin probing the mechanisms that may underlie gender differences.

Management of Progressive Disease in Idiopathic Pulmonary Fibrosis
https://clinicaltrials.gov/ct2/show/NCT03939520

Jan 21st, 2022 - Idiopathic pulmonary fibrosis (IPF) is a prototype of chronic, progressive, and fibrotic lung disease. It has been considered rare, with an incidence estimated to 11.5 cases per 100 000 individuals per year. Increasing rates of hospital admissions and deaths due to IPF suggest an increasing burden of disease. The median survival time from diagnosis is 2-4 years. Recently two disease-modifying t...

A Study of a Candidate COVID-19 Vaccine (COV001)
https://clinicaltrials.gov/ct2/show/NCT04324606

Jan 21st, 2022 - There will be 4 study groups and it is anticipated that a total of 1090 volunteers will be enrolled. Volunteers will participate in the study for approximately 12 months from last vaccination visit (approximately 15 months from enrolment for participants receiving 2 doses)

Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial
https://clinicaltrials.gov/ct2/show/NCT04324463

Jan 21st, 2022 - The ACT COVID-19 program consists of two parallel trials testing the effects of interventions in complementary populations in outpatients and inpatients. In the outpatient study, symptomatic patients in the community who are COVID-19 positive and at high risk of disease progression: colchicine compared with control (anti-inflammatory); and ASA compared with control (anti-thrombotic); using a 2 ...

A Remote, Decentralized Opioid Use Disorder Study to Evaluate Patient Engagement With a Game-Based Digital Therapeutic
https://clinicaltrials.gov/ct2/show/NCT04542642

Jan 21st, 2022 - This is a randomized, controlled, open-label, decentralized study to evaluate patient engagement with PEAR-008, a game-based digital therapeutic for the treatment of opioid use disorder. PEAR-008 is a new version of reSET-O, an FDA-authorized mobile application treatment (available by prescription only) for opioid use disorder. The study will examine if changing the application's delivery forma...

Collaboration Leading to Addiction Treatment and Recovery From Other Stresses
https://clinicaltrials.gov/ct2/show/NCT04559893

Jan 21st, 2022 - Untreated mental illness and substance use disorders are prevalent and can have devastating consequences for the individual, their families and the community. Co-occurring opioid use disorders (OUD) with either depressive disorders and/or post-traumatic stress disorder (PTSD) are of particular concern, because depression and PTSD are prevalent in people with OUD, co-occurring mental illness is ...

Adjuvant Aspirin Treatment for Colon Cancer Patients
https://clinicaltrials.gov/ct2/show/NCT02467582

Jan 21st, 2022 - Colorectal cancer is the third most common malignancy for both women and men and is responsible for almost 10% of all cancer death. Despite complete removal of the tumor and use of adjuvant chemotherapy, up to 25% of patients with stage II colon cancer and up to 50% of patients with stage III disease will suffer from recurrences, which is associated with poor prognosis. Several retrospective ob...

Molecular Effects of Aspirin & Metformin on Colonic Epithelium
https://clinicaltrials.gov/ct2/show/NCT05158374

Jan 21st, 2022 - Colorectal cancer (CRC) is eminently preventable, and yet it is the 2nd most common cause of cancer death in the UK. Both population growth and ageing will influence CRC incidence. There is a significant environmental aetiological component, with around 54% being preventable. Modifiable risk factors include obesity, metabolic syndrome, type 2 diabetes mellitus (T2DM), and physical inactivity.Re...

Biased Opioid Agonists for Treatment of Opioid Withdrawal in OUD
https://clinicaltrials.gov/ct2/show/NCT04316559

Jan 21st, 2022 - Background. Opioid-agonist medications (methadone and buprenorphine) are the most effective treatments available for opioid addiction. However, they are not effective in all cases, and with the vast number of people requiring treatment in the current crisis, even a modest increase in the percentage of people who respond to treatment would represent a substantial benefit in public health. Recent...

Analgesia for Thyroidectomy Using Bilateral Superficial Cervical Plexus Block With Bupivacaine Only or Adding Ketorolac to it.
https://clinicaltrials.gov/ct2/show/NCT05180214

Jan 21st, 2022 - Thyroidectomy is considered a common operation with moderate to severe postoperative pain in some patients. Patients are divided into two groups. Bupivacaine group received bilateral superficial cervical plexus block (BSCPB) with 10 ml of bupivacaine (0.25%) and 1 ml of normal saline on each side and the Bupivacaine Ketorolac group received (BSCPB) with 10 ml of bupivacaine (0.25%) and 1 ml of ...

A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy
https://clinicaltrials.gov/ct2/show/NCT05200806

Jan 21st, 2022 - Our primary objectives are: Determine the rate of patients needing rescue narcotics prescriptions for breakthrough postoperative pain after colectomy while on a non-narcotic postoperative protocol. Search for patterns pain and in timing of need for narcotic medication (e.g. in PACU, after intrathecal morphine wear off, etc.) Secondary objectives: Measure patient satisfaction with pain managemen...

Efficacy and Safety of Butorphanol Tartrate Injection for the Patients With Mechanical Ventilation
https://clinicaltrials.gov/ct2/show/NCT05201560

Jan 21st, 2022 - Butorphanol can improve inflammation and promote the recovery of pro-inflammatory/anti-inflammatory cytokine balance.However, there is still a lack of relevant clinical studies on butorphanol and fentanyl for the incidence of hospital-acquired infections in ICU mechanically ventilated patients.The objective of this study was to evaluate the analgesic efficacy,safety and the incidence of nosocom...

Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression
https://clinicaltrials.gov/ct2/show/NCT02726659

Jan 20th, 2022 - The investigators will conduct a 6-week, randomized, double-blind, placebo-controlled trial of celecoxib as an add-on treatment to the mood stabilizer among women with bipolar I or II postpartum depression. Women who are taking a mood stabilizer for treatment of bipolar disorder in the postpartum treatment will receive either a placebo or celecoxib add-on treatment. Patients will be monitored r...